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Available online 20 February 2008The notion that prosaposin (Prosap) is likely involved in brain development and regeneration led us to explore
its expression in stem/progenitor neural cells and its fate after cell differentiation. The expression of
procathepsin–cathepsin D (proCath–Cath D), an endoprotease that plays an important role in the processing
and sorting of Prosap, has been concomitantly examined. Our data evidenced that in embryonic human neural
progenitor cells (eHNPCs) intact and high molecular weight intermediate forms of Prosap and intermediate
forms of Cath D accumulated inside the cells, while the formation of saposins and mature Cath D was
impaired. Furthermore, neither Prosap nor proCath Dwere secreted from eHNPCs. The block of the processing
and secretion shared by Prosap and proCath D was overcome during the course of differentiation of eHNPCs
into a mixed population of astrocytes and neuronal cells. Upon differentiation, large amounts of Prosap and
proCath D were secreted from the cells, while saposins and mature Cath D were produced inside the cells. The
dramatic accumulation of Prosap (an antiapoptotic factor) and reduction of mature Cath D (a proapoptotic
factor) in the undifferentiated eHNPCs most likely play a role in the molecular mechanisms regulating the
resistance to apoptotic signals of these cells and might represent a critically important issue in HNPCs biology.
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Prosaposin (Prosap) is a glycoprotein of 65–73 kDa mass proteoli-
tically cleaved in late endosomes/lysosomes to give rise to four small
glycoproteins, saposin (Sap) A, B, C and D [1,2]. Saps play an important
role as intracellular activators of several lysosomal enzymes involved in
the degradation of speciﬁc sphingolipids; Sap A favours the degradation
of galactosylceramide [3], Sap B that of sulfatide [4,5], Sap C that
of glucosylceramide [6] and Sap D that of ceramide [7]. Recently, the
involvement of Saps in lipid antigens presentation has been also
demonstrated [8,9].
Besides being the precursor of Saps, Prosap is also a secretory protein
present in several biological ﬂuids such as cerebrospinal ﬂuid, milk and
seminiferous tubule ﬂuid [10–12]. The sorting of Prosap to intracellular
organelles or to extracellular spaces is speciﬁcally regulated in different
human and animal tissues by as yet not clearly deﬁned signals. It has
been proposed that sphingomyelin-containing raft and the Sap D
domainwith its adjacent COOH-terminal regionplay a crucial role in the
transport of Prosap to lysosomes [13,14].Moreover, sortilin, a transmem-
brane proteinwithmultiple ligand-binding domains, possibly mediates
the Prosap sorting in speciﬁc tissues [15]. After reaching lysosomes,
Prosap is converted to Saps by lysosomal proteases. Several lanes of39 06 49387087.
aro).
l rights reserved.evidence have demonstrated the involvement of cathepsin (Cath) D in
the lysosomal Prosap proteolysis [16].
Prosap is expressed in all cell types and its expression is temporally
and spatially regulated at transcriptional and post-translational levels
[17,18]. Prosap is present at high concentration in brain, being localized
in speciﬁc neurons and nerve ﬁbres [19,20]. Abundant Prosap ex-
pressionhas been found in the epithelial cells of the choroid plexus and
in various gray matter areas, including cortex and hippocampus
[17,21].
While some of the physiological roles of Saps, the lysosomal
proteolytic products of Prosap, are well deﬁned, the actual function of
intact Prosap is still uncertain. A pivotal role for Prosap in development
and regeneration of brain has beenproposed [22]. It has been observed
that Prosap functions ‘ex vivo’ as a neurotrophic and antiapoptotic
factor and that exogenous addition of Prosap to neuronal cells leads to
neurite outgrowth, prevents cell death and promotes the nerve
regenerationprocesses [23–27]. Furthermore, the expression of Prosap
markedly increases in response to brain injury, after ischemia and
following sciatic nerve crush injury [22,28,29]. In this context it is
worthwhile to note that recent studies have shown that after a brain
lesion neural progenitor cells (NPCs) are activated, migrate from their
niche towards lesion areas, where differentiate into neuronal and glial
cells [30,31]. The parallel increase in the brain injured areas of theNPCs
population and of the Prosap expression strongly suggests a relation-
ship between these two events.
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Prosap an ideal candidate as a protein factor able to modulate the well
known high regenerative capacity of NPCs and their high resistance to
apoptotic signals. Although the discrete distribution of Prosap in animal
brains has been previously described, no information is available about
its expression in the human NPCs population. To further extend the
search for proteins that might contribute to determine the biological
responses of human neural progenitor cells (HNPCs), we have thus
investigated the expression and properties of Prosap in these cells and
its fate after differentiation. Since proCath–Cath D plays an important
role in the trafﬁc and processing of Prosap [32], the expression and
properties of this endoprotease has been simultaneously examined in
details. The study of the Cath D behaviour in HNPCs is of particular
interest not only for its relationshipwith Prosap, but also because CathD
is considered an important mediator in the control of cell death [33].
Hereinwe uncovered a dramatic intracellular accumulation of Prosap (a
protein with neurothophic and antiapoptotic effects) and a markedly
reduced level of mature Cath D (a protein with proapoptotic effect) in
embryonic HNPCs (eHNPCs). The altered expression and post-transla-
tional modiﬁcations of these two proteins most likely have a role in
modulating the eHNPCsproliferation and resistance to apoptotic signals.
2. Materials and methods
2.1. Cell culture
2.1.1. Human neural progenitor cells
Adult humanneural progenitor cells (aHNPCs)were obtained from the olfactory bulb
of patients undergoing particularly invasive neurosurgery as previously described
[34,35]. Embryonic human progenitor cells (eHNPCs) were purchased from Cambrex
(Walkersville, MD). HNPCs were cultured in DMEM-F12 (1:1) (Invitrogen, Carlsbad, CA)
supplemented with 20 ng/ml of human recombinant epidermal growth factor (EGF),
10 ng/ml of human recombinant basic ﬁbroblast growth factor (bFGF), 2 mM glutamine,
0.6% glucose, 9.6 µg/ml putrescine, 6.3 ng/ml progesterone, 5.2 ng/ml sodium selenite,
0.025 mg/ml insulin, and 0.1 mg/ml transferrin. The cells were used from passage 2 to 5
throughout the study.
HNPCs were differentiated by plating them on Matrigel (Becton Dickinson) in
DMEM-F12 (1:1) medium lacking growth factors but added with 5% fetal bovine serum
(FBS). The cells were allowed to differentiate for up to 21 days. Differentiation was
evaluated by cell morphology and by confocal microscopy analysis of neuronal marker
β-III tubulin and astrocyte marker glial ﬁbrillary acidic protein (GFAP).
2.1.2. Fibroblasts
Fibroblast cultures were established from skin explants of normal individuals.
Fibroblasts were cultured in DMEM (Invitrogen, Carlsbad,CA) supplemented with 10%
FBS, 2 mM glutamine, 100 units/ml of penicillin and 100 μg/ml streptomycin. The cells
were harvested after reaching conﬂuency.
2.1.3. Neuroblastoma cells
Human neuroblastoma cells SHSY5Y were cultured in MEM/Ham's F12 (1:1
mixture) (Invitrogen, Carlsbad,CA) supplemented with 10% FBS, 2 mM glutamine,
100 U/ml of penicillin and 100 μg/ml streptomycin. The cells were harvested after
reaching conﬂuency.
2.2. Antibodies
Rabbit polyclonal anti-human Sap C antibody was prepared in our laboratory [36].
It recognizes both Sap C and Prosap. Rabbit polyclonal anti-human Cath D antibody was
obtained from DakoCytomation (Glostrup, DK) and mouse monoclonal anti-Cath D
antibody was obtained from Sigma Aldrich (St. Louis, MO). Mousemonoclonal anti-Cath
B antibody was obtained from Calbiochem (Darmstadt, Germany). Mouse monoclonal
anti-human lysosome-associated membrane protein type 1 (LAMP 1) antibody, was
obtained from the Developmental Studies Hybridoma Bank, maintained by the
University of Iowa (Iowa City, IA). Anti-actin monoclonal antibody was obtained from
Oncogene Research Products (Boston, MA).
2.3. Western blot analysis
Cell pellets werewashed twicewith cold PBS and resuspended in 50mMphosphate
buffer, pH 6.5, containing 0.5% (v/v) Triton X-100 and one tablet of protease inhibitor
mixture (Roche Applied Science)/50 ml (lysis buffer). After brief sonication the
homogenates were centrifuged for 30 min at 20,000 ×g at 4 °C. Lysates were resolved
on NuPAGE 4–12% Bis–Tris gels using a mini-gel apparatus (Invitrogen) and transferred
to polyvinylidene diﬂuoride (PVDF) membranes (Bio-Rad Laboratories, Inc. Hercules,
CA). Membranes were blocked for 1 h with 2% nonfat milk powder in PBS containing
0.1% Tween-20 and incubated for 1 h with speciﬁc antibodies. Primary and secondaryantibodies were diluted in blocking solution. Immunoreactive proteins were visualized
using an ECL Western blotting kit, according to the manufacturer's instructions
(Amersham Bioscience, Buckinghamshire, UK).
2.4. Glycosidase treatment
An aliquot of cell lysate was adjusted to pH 7.5 with 50mM sodium phosphate, while
another aliquot was adjusted to pH 5.5 with 50 mM sodium citrate. The ﬁrst sample was
incubated with peptide-N-glycosidase F (PNGase F) and the second with β-endo-N-
acetylglucosaminidase H (Endo H) in the presence of appropriate reagents supplied
together with the glycosidases by New England BioLabs Inc. (Beverly, MA). The samples
were incubated according to the manufacturer's instructions and then loaded on NuPAGE
4–12% Bis–Tris gels, subjected to electrophoresis, transferred to PVDF membranes and
analyzed by Western blotting utilizing the anti-Sap C antibody as described above.
2.5. Real-Time PCR and analysis of Prosap exon 8 isoforms
Total RNAwas extracted with TRIzol® Reagent (Invitrogen). 1 μg of RNAwas reverse
transcribed in a 20 μl reactionmixture using M-MLV Reverse Transcriptase (Invitrogen).
The relative quantiﬁcation of human Prosap mRNA was performed by TaqMan
technology, using the ABI PRISM 7900 DNA sequence detection system (Applied
Biosystems). Commercial ready-to-use primers/probe mixes were used (Assay-on-
Demand Gene Expression products, Hs00358165_m1; Applied Biosystems). Ampliﬁca-
tion was performed with 40 cycles of 15 s at 95 °C and 1 min at 60 °C. Human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping
gene. Original input RNA amounts were calculated with a relative standard curve for
Prosap and GAPDH mRNA. Gene expression values were reported as the normalized
percentage obtained by dividing the copy numbers of speciﬁc gene by GAPDH.
To examine Prosap isoforms, cDNA was used in a PCR reaction to amplify a region
encompassing the Exon-8 sequence of the human Prosap gene. A set of primers previously
described [22] were utilized, namely hB1 (5′-AAGAACTATATCAGCCAGTAT-3′) and hB2 (5′-
TTTCACCTCATCACAGAACCC-3′). PCR reactionwas performed by 35 cycles of 30 s at 94 °C,
30 s at 56 °C and 1 min at 72 °C. PCR products were separated by electrophoresis on 8%
polyacrylamide gel.
2.6. Metabolic labeling of cells
Prior to being labeled eHNPC or ﬁbroblasts (grown until near conﬂuency) were
washed twice with ice-cold PBS supplemented with 1 mM MgCl2 and 0.1 mM CaCl2.
Fibroblasts were then starved for 2 h in methionine/cysteine-deﬁcient DMEM
supplemented with 4% FBS, 2 mM glutamine, 100 U/ml of penicillin and 100 μg/ml
streptomycin, while eHNPCs were starved for 2 h in a medium prepared as described in
the cell culture section except that DMEM-F12 (1:1) was substituted with methionine/
cysteine-deﬁcient DMEM. For pulse experiments PRO-MIX L-[35S] (Amersham Bios-
ciences, Buckinghamshire, UK) 150 µCi/ml was added to the medium and the cells
(eHNPCs or ﬁbroblasts) were further cultured for the indicated periods. For experiments
including chase periods, after 1 h of pulse the cells were washed three times with PBS
and then culturedwith theirmediumdevoid of PRO-MIX L-[35S] and supplementedwith
5 mM methionine. For pulse and pulse-chase experiments on differentiated cells, the
eHNPCswere previously allowed to differentiate for up to 14 days as described in the cell
culture section. The cells were then starved for 2 h inmethionine/cysteine-freemedium
and than pulsed or pulse-chased for the indicated periods.
2.7. Immunoprecipitation
The cells, labeled as described above, were harvested and disrupted in lysis buffer.
The suspensions were subjected to brief sonication and centrifuged at 20,000 ×g for
30 min at 4 °C. To remove DNA and histones, the supernatants were incubated with
0.03% protamine sulfate for 45 min at 4 °C and centrifuged as above. After addition of
0.1% BSA, the cell lysates were incubated with pre-immune serum overnight at 4 °C and
non-speciﬁc complexes were precipitated with Protein A-Sepharose CL-4B (Sigma
Aldrich, St. Louis, MO). The clariﬁed supernatants were then incubated overnight with
anti-Sap C or anti-Cath D antiserum. Cross-reacting material was precipitated with
Protein A-Sepharose CL-4B. The immunocomplexes were washed four times with PBS
containing 1% BSA, 1% Triton X-100, 1% SDS, 0.4% sodium deoxycholate and ﬁnally with
only PBS. The washed precipitates were analyzed by SDS-PAGE. Labeled proteins were
detected by ﬂuorography.
2.8. Cath D activity
Cell pellets (HNPCs andﬁbroblasts)were lysed inwater containing 0.5% CHAPS (w/v)
for 30 min on ice. The suspension was centrifuged at 15,000 ×g for 20 min at 4 °C. The
activity of Cath D was assayed on the supernatants using the ﬂuorogenic substrate
MOCAc-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys (Dpb)gamma-NH2 (Peptide Interna-
tional) as described by Yasuda et al. [37].
2.9. Microscopy
eHNPCs (undifferentiated and differentiated) and human ﬁbroblasts were grown
on polylysine-coated glass coverslips for microscopy. After a ﬁxing step in Bouin's
Fig. 1. Comparison of the Prosap and Saps levels in HNPCs, neuroblastoma cells and human ﬁbroblasts. (A) Western blotting of Prosap and Saps in homogenates of human ﬁbroblasts,
eHNPCs, neuroblastoma cells (SHSY5Y) and aHNPCs. Identical amounts of homogenates (5 µg of protein) were loaded in each lane and analyzed by SDS-PAGE/Western blot with an
anti-Sap C antibody that recognizes Prosap and Sap C. The blotswere reprobed for ß-actin as a loading control. The number on the left refers tomolecular mass standards (in kDa). The
arrows on the right indicate the molecular weights of the intact and intermediate forms of Prosap and of mature Sap C. The experiment was repeated more than three times giving
similar results. (B) Relative levels of intact and intermediate forms of Prosap (MW 66 kDa and 47 kDa, respectively) were evaluated by densitometric analysis of the Prosap bands
normalized against the ß-actin bands. (C) ProsapmRNA expression in ﬁbroblasts, eHNPCs, neuroblastoma cells (SHSY5Y) and aHNPCs. ProsapmRNA amounts were normalized to and
presented as percentages of GAPDH for each sample. The data represents the means+S.E.M. of three independent experiments.
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with PBS and incubated 2 h with 3% BSA.
For the immunoﬂuorescence analysis of the antigenic markers expression in
astrocytes and neurons, slides were incubated for 1 h at 37 °C with antineuron-speciﬁc
ß-III tubulin-speciﬁc antibody (mouse IgG1; Serotec Inc., Munich, Germany) and anti-
glial ﬁbrillary acid protein (GFAP) (rabbit polyclonal; Dako Cytomation). Nuclei were
counterstained with TOTO-3 iodide (Molecular Probes). After two washes in PBS, slides
were incubated with secondary antibodies for 45 min at 37 °C. Secondary antibodies,
including FITC-conjugated goat anti-mouse IgG and Texas red-conjugated donkey anti-
rabbit IgG (Jackson ImmunoResearch Laboratories) were used at 2.5 µg/ml.
For double immunostaining, the cells were incubated for 1 h at room temperature
with a speciﬁc rabbit polyclonal antibody (anti-Sap C) together with a speciﬁc mouse
monoclonal antibody (anti-Cath D or anti-Lamp1). Cells were then rinsed twice with
PBS, and incubated for 1 h with a secondary anti-rabbit antibody conjugated with AlexaFig. 2. Prosap processing and secretion. Human ﬁbroblasts (A and C) and eHNPCs (B and D
experiments) or, alternatively, labeled for 1 h and subsequently chased for the indicated t
immunoprecipitated with anti-Sap C antibody that recognizes Prosap and Sap C. Immunopr
the left refers to the molecular mass of standards (in kDa). The experiments were repeatedFluor 594, together with a secondary anti-mouse antibody conjugated with Alexa Fluor
488 (Molecular Probes). Cells were ﬁnally rinsed twice with PBS and mounted with
ProLong antifade reagent (Molecular Probes). Images were collected with a laser
scanning microscope (IX81; Olympus, Suffolk, UK).
3. Results
3.1. Expression of Prosap in HNPCs
To investigate whether neural stem/progenitor cells might con-
tribute to the Prosap overexpression previously observed in speciﬁc
regions of the brain [17,19,20], we have analyzed the intracellular) were labeled with [35S] methionine/cysteine for the indicated times (A and B, pulse
imes (C and D, pulse-chase experiments). Both the cell-lysates and the medium were
ecipitates were separated by SDS-PAGE and visualized by ﬂuorography. The number on
more than three times giving similar results.
Fig. 3. Endoglycosidase treatment of Prosap. Cell extracts from ﬁbroblasts (100 µg) and
from eHNPCs (10 µg) were treated either with PNGase F or with Endo H as described in
Materials and methods. The samples were then analyzed by SDS-PAGE/Western blot
with the anti-Sap C antibody. The number on the left refers to the molecular mass of
standards (in kDa). The experiments were repeated more than three times giving
similar results.
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much higher level of intact (about 66 kDa) and partially processed
forms (about 47 kDa) of Prosap in eHNPCs when compared with
aHNPCs or with a neuronal-like cell type such as SHSY5Y or with
human ﬁbroblasts (Fig. 1A). Conversely, the band corresponding to
mature Sap C (about 10 kDa) was clearly detected in all the examined
cell types except than in eHNPCs. The densitometric analysis showed
that the intensity of the intact Prosap band at 66 kDa in eHNPCswas at
least 4 times stronger than the corresponding band in aHNPCs and
SHSY5Y and at least 20 times stronger than that observed in
ﬁbroblasts. Moreover, the Prosap band at about 47 kDa observed in
eHNPCs was almost absent in the other cells (Fig. 1B).
In order to evaluate whether the accumulation of Prosap in
eHNPCs was related to an increase of the Prosap mRNA expression,Fig. 4. ProCath-Cath D expression. (A) Cath D activity was determined in extracts of eHNPCs
extracts. The blots were reprobed for ß-actin as a loading control. The number on the left
molecular weights of Cath D and Cath B isoforms. (C) Densitometric analysis of the Cath D b
labelled with [35S] methionine/cysteine for the indicated times. Both the cell lysates and th
precursor, intermediate and mature isoforms. Immunoprecipitates were separated by SDS-PA
of standards (in kDa). The experiments were repeated more than three times giving similarReal-Time PCR analysis was performed. For correction of minor vari-
ations in input amounts of RNA samples, mRNA levels were normal-
ized to the amount of GAPDH for each sample (Fig. 1C). A comparison
between Fig.1B with Fig.1C shows that therewas no direct correlation
between Prosap mRNA and protein level in the examined cells. For
example, the dramatic difference in the Prosap protein amount
between eHNPCs and ﬁbroblasts did not correspond to an analogous
difference at mRNA level. These results indicate that the accumulation
of the Prosap protein in eHNPCs, was not solely due to mRNA over-
expression, but also to post-translational events.
In an effort to deﬁne such events, we have compared the Prosap
processing and sorting in eHNPCs and in human ﬁbroblasts, a cell type
where processing, trafﬁcking, secretion and post-translational mod-
iﬁcations of Prosap/Sap have been extensively characterized [1,2]. The
cellswere labeled for different periods of time and both the cell-lysates
and the growth medium were immunoprecipitated with an antibody
which recognizes Prosap and Sap C. Fig. 2A shows that in human
ﬁbroblasts Prosap was synthesized as a protein with an apparent
molecular mass of 66 kDa. Within approximately 5 h, two bands
corresponding to small Saps (MWabout 10 kDa) became detectable in
the ﬁbroblast extract. After 24 h the intensity of the bands at ~10 kDa
overcame that of intact Prosap, that was also exported as such into the
external medium. Conversely, in eHNPC the Prosap forms at high
molecular weights (the 66 kDa intact and the 47 kDa intermediate
forms) were the predominant ones also after 24 h of pulse, when faint
bands corresponding to mature Saps became visible. Moreover, only
trace amounts of intact Prosap were immunoprecipitated from the
eHNPCs medium (Fig. 2B). To further conﬁrm the block of Prosap
processing and sorting, pulse-chase experimentswere performed. The
cells were pulse-labeled for 1 h and then chased for different times
(Fig. 2C and D). After 5 h of chase most of Prosap was proteolitically, aHNPCs and ﬁbroblasts. (B) Western blot analysis of Cath D and Cath B isoforms in the
refers to molecular mass of standards (in kDa). The arrows on the right indicate the
ands normalized against the ß-actin bands. (D) eHNPCs and (E) human ﬁbroblasts were
e medium were immunoprecipitated with an anti-Cath D antibody that recognizes the
GE and visualized by ﬂuorography. The number on the left refers to the molecular mass
results.
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10%) was observed in eHNPCs. After 24 h of chase, the conversion of
Prosap produced an equivalent amount of Saps in ﬁbroblasts, but only
trace amounts in eHNPCs. Concomitantly, the analysis of the cell
medium revealed an abundant secretion of intact Prosap from
ﬁbroblasts, but not from eHNPCs. These results indicate that the
Prosap transport to extracellular spaces and its intracellular conversion
to Saps are inhibited or are not activated at all in eHNPCs.
3.2. Endoglycosidase treatments of Prosap
It has been previously observed that the sugar chains linked to
intracellular Prosap differ from those linked to the Prosap form
exported outside the cells, suggesting a relation between oligosac-
charide processing and sorting [14,38]. To investigate the molecular
factors determining the intracellular retention of Prosap in eHNPCs,
we have examined the structure of its N-linked carbohydrates. To this
aim homogenates of eHNPCs were digested either with Endo H, which
hydrolyzes high mannose oligosaccharides or with PNGaseF, which
hydrolyzes asparagines-linked glycans of both high mannose and
complex types [39,40]. For comparison, ﬁbroblasts homogenates were
also incubatedwith the two endoglycosidases. As shown in Fig. 3, both
endo H and PNGase F treatment of ﬁbroblasts resulted in the total
conversion of Prosap into the 55 kDa deglycosylated form, conﬁrmingFig. 5. Detection of Prosap-Sap and Procath-Cath D isoforms in eHNPCs during their differentiat
differentiation (day 0) and after 1 and 7 days of culture in the differentiation medium (see Ma
tubulin-speciﬁc antibody (green) and anti-GFAP antibody (red) to conﬁrm the differentiation in
TOTO-3 iodide (blue). Scale bars in the micrographs and in the immunostained ﬂuorescent ima
undifferentiated eHNPCs (day 0) and from eHNPCs cultured for 7, 14 and 21 days respectively in
antibodies against Sap C, Cath D and ß-actin (as loading control). A representative Western b
molecular mass of standards (in kDa).that intracellular Prosap contains only high mannose sugars in these
cells. Conversely, treatment with Endo H of eHNPCs homogenate
produced diffuse bands between 65 and 55 kDa, presumably cor-
responding to partially deglycosylated forms (Fig. 3). This result
indicates that in eHNPCs Prosap contains both types of oligosacchar-
ides (high mannose type and complex asparagine-linked glycans) in
one protein molecule.
3.3. Expression of Cath D in HNPCs
In most cell types intracellular Prosap is almost completely
converted into Saps by the action of lysosomal proteases, especially
of the aspartyl endoproteinase Cath D [12,16]. The observed intra-
cellular accumulation of Prosap in eHNPCs and, to a lesser extent, in
aHNPCs, prompted us to investigate whether the delayed/abolished
Prosap proteolysis might be related to low Cath D activity. The
ﬂuorogenic substrate MOCAc-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-
Lys (Dpb)gamma-NH2 was utilized to evaluate the proteinase activity
in cell homogenates [37]. As shown in Fig. 4A, a markedly reduced
Cath D activity (15–20% of that in ﬁbroblast homogenate) was mea-
sured in eHNPCs and aHNPCs.
To assess whether the low activity was related to the presence of a
low amount of Cath D protein, Western blot analysis using an anti-
Cath D antibody that recognizes unprocessed and processed Cath Dion into astrocytes and neurons. (A) Representative images of eHNPCs neurospheres before
terials and methods). Cells on day 7 of differentiation were also immunostained with ß-III
to GFAP-positive astrocytes and tubulin-positive neurons. Nuclei were counterstainedwith
ge indicate 500 µm and 100 µm, respectively. (B) Equal amounts (10 µg) of cell lysates from
differentiation medium (see Materials andmethods) were analyzed byWestern blot with
lot out of three independent experiments is shown. The number on the left refers to the
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intermediate (48–45 kDa) and mature (33–30 kDa) isoforms [41].
Fig. 4B and C show that the relative abundance of the different Cath D
isoforms in eHNPCs, aHNPCs and ﬁbroblasts is markedly different. The
intensity of the 30 kDa band, corresponding to the mature double-
chain formwas much weaker in HNPCs (especially in eHNPCs) than in
ﬁbroblasts. Conversely, a band at about 43 kDa, presumably repre-
senting an intermediate Cath D form, was detected in HNPCs, but not
in ﬁbroblasts. Cath B, another lysosomal cathepsin evaluated as a
control, was present as a mature 27 kDa form in both HNPCs and
ﬁbroblasts homogenates (Fig. 4B).
To conﬁrm the reduced formation of the mature 30 kDa form of
Cath D in eHNPCs and to evaluate the secretion of the precursor form,
pulse experiments have been performed. As shown in Fig. 4D, the
main intracellular forms found after 24 h of continuous labeling were
the precursor (~50 kDa) and the intermediate (~43 kDa) forms, while
the mature form (30 kDa) was hardly visible. On contrast, in
ﬁbroblasts homogenates the mature form of Cath D was already the
predominant one after 5 h of pulse (Fig. 4E). Concomitantly, the
amount of the precursor form (~50 kDa) increased in the medium of
ﬁbroblasts in a time-dependent manner, while only trace amounts
were detected in the media of eHNPCs. These results indicate that in
eHNPCs proCath D, likewise Prosap, is poorly processed and secreted.
3.4. Expression of Prosap and proCath D during differentiation of eHPNCs
To investigate whether the observed behaviour of Prosap and
proCath D was related to the undifferentiated state of eHNPCs, we
examined the expression of these two proteins during differentiation.
The cells were induced to differentiate by cultivating them in the
presence of FBS. Under this experimental condition, eHNPCs mainly
differentiated into astrocytes and neurons (Fig. 5). Semiquantitative
evaluation of the antigenic markers expression indicated that
differentiated cultures contained about 80% GFAP-positive astrocytes,
about 10% of β-III tubulin-positive neurons and rare astroglia (Fig. 5A).
Western blot analysis revealed that differentiation caused a decreaseFig. 6. Processing and secretion of Prosap and proCath D after differentiation of eHNPCs. eH
labelled with [35S] methionine/cysteine for 5 h or 24 h (A and C, pulse experiments) or, a
experiments). Prosap–Sap (A, B) and proCath–cath D (C, D) were immunoprecipitated from ce
separated by SDS-PAGE and visualized by ﬂuorography. The number on the left refers to the
times giving similar results.of the 66 kDa intact Prosap, the disappearance of the intermediate
45 kDa form and amarked increase of themature forms of Saps (about
10 kDa) already evident after a week of culture in the differentiation
medium. Simultaneously, the level of the mature form of Cath D
(30 kDa) dramatically increased (Fig. 5B).
The time-dependent formation of mature Saps and mature Cath D
in the differentiated cells was conﬁrmed by pulse and pulse-chase
experiments (Fig. 6). Cells, that were cultivated for two weeks in FBS-
containing medium, were pulse-labeled with [35S]methionine/
cysteine and harvested after various time periods. After 5 h of labeling
two bands at about 10 kDa corresponding to Saps appeared and their
intensity dramatically increased after 24 h (Fig. 6A). A similar increase
in the formation of the mature form of Cath D (30 kDa) was observed
(Fig. 6C). Moreover, the differentiated cells were able to export large
amounts of the intact form of Prosap and proCath D in the medium.
(Fig. 6A and C). Pulse-chase experiments (1 h of pulse and 5 and 24 h of
chase) conﬁrmed the conversion of Prosap into Saps and of proCath D
into mature CathD (Fig. 6B and D). These results indicate that the
differentiationprocess of eHNPCs promotes the intracellular lysosomal
proteolysis and the extracellular sorting of both Prosap and proCath D.
3.5. Subcellular localization of Prosap–Sap and proCath–Cath D in
undifferentiated and differentiated eHNPCs
The above results show that, while high molecular forms of
Prosap–Sap and of proCath–Cath D are the main forms present in
undifferentiated eHNPCs, large amounts of mature Saps and Cath D
are generated after differentiation. The precursors and mature forms
of these proteins presumably reside in different compartments of the
cells. To compare their subcellular localization before and after
differentiation, immunostaining experiments were carried out utiliz-
ing anti-Sap C and anti-CathD antibodies that recognize the precursor
and mature forms. Confocal microscopy revealed that in the
undifferentiated eHNPCs Prosap did not colocalize with the lysosomal
marker Lamp1 but was located on and near the cell surface (Fig. 7A).
This result indicates that intact and high molecular intermediateNPCs were cultured for 14 days in the differentiation medium and then metabolically
lternatively, labeled for 1 h and chased for the indicates times (B and D, pulse-chase
ll lysates andmediumwith the respective speciﬁc antibodies. Immunoprecipitates were
molecular mass of standards (in kDa). The experiments were repeated more than three
Fig. 7. Confocal microscopy of Prosap–Sap and proCath–Cath D in undifferentiated and differentiated eHNPCs. Undifferentiated eHNPCs (A) or eHNPCs after 14 days of culture in the
differentiation medium (B) or human ﬁbroblasts (C) were double-immunostained for Lamp1 and Prosap–Sap or for proCath–Cath D and Prosap–Sap. The right panels show the
merged images. Bars, 10 μm (A and B), 20 μm (C).
Fig. 8. Alternative 9-bp splicing of Prosap mRNA during eHNPCs differentiation. Total
RNA from eHNPCs before and after differentiation for 7, 14 and 21 days was subjected to
RT-PCR and the products were separated by gel electrophoresis on 8% acrylamide gel as
described in Materials and methods. A representative result was shown in the Figure.
Note the presence of a 111 bp and a 102 bp band representing transcripts with or
without the 9-bp insertion sequence (exon 8) [22].
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compartments of the cells distinct from late endosomes/lysosomes.
Fig. 7A shows that also proCath–Cath D is localized near the cell
plasma membrane, partly colocalizing with Prosap.
When eHNPCs were induced to differentiate, Cath D and Sap C
were detected in vesicles that also contained Lamp1 (Fig. 7B),
indicating that the mature forms of the two proteins mostly reside
in the late endosomes/lysosomes of the differentiated cells. As a
control human ﬁbroblasts were examined under the same experi-
mental conditions; a complete colocalization of Sap C, Cath D and
Lamp1 was observed in these cells, as expected (Fig. 7C).
3.6. Alternative Prosap mRNA splicing during differentiation of eHPNCs
It has been previously shown that in human and animal brains
Prosap mRNA is present as two major isoforms differing in the
inclusion of 9 bps of exon 8 within the Sap B domain [42]. In normal
rat brain the two Prosap mRNA species with and without the 9 base
insertion are expressed at a ratio of 85:15 and this equilibrium isreverted to 5:95 following ischemic injury [22]. In order to evaluate
whether the differentiation process might also affect the Prosap
mRNA splicing, we assessed the abundance of Prosap mRNAwith and
without exon 8 in eHNPCs and in their differentiated progeny. The
experimental approach described by Hiraiwa et al. [22] was followed.
As shown in Fig. 8, the abundance of Prosap mRNAs with exon 8 was
markedly higher than that without exon 8 in the undifferentiated
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a time-dependent manner, becoming the predominant one after
14 days of differentiation treatment. Thus, the alternative splicing of
Prosap mRNA, that has been previously observed following brain
injury [22], occurs also upon eHNPCs differentiation (Fig. 8).
4. Discussion
Although neural stem/progenitor cells have recently received
much attention for their therapeutic potential in the treatment of
various neurological diseases or injuries [43], several aspects of their
biological behaviour are ill deﬁned. In the present investigation we
have studied in HNPCs the expression of Prosap, a protein proposed to
play important roles in the nervous system, and of Cath D, a lysosomal
aspartyl endoproteinase involved in the transport and proteolytic
conversion of Prosap into Saps [16]. We have found that eHNPCs
accumulate inside the cells large amounts of intact and highmolecular
weight intermediate forms of the Prosap protein, while the formation
of mature Saps was blocked. Concomitantly, accumulation of an
intermediate form of Cath D and a minute amount of mature Cath D
were detected. Moreover, eHNPCs did not export neither Prosap nor
proCath D outside the cells.
Quantitative real-time PCR showed that HNPCs contained more
Prosap mRNA than other cell types such as neuroblastoma cells
(SHSY5Y) or ﬁbroblasts, but the different gene expressions did not
correlate with the observed differences in the level of intact Prosap
proteinwithin these cells. The accumulation of Prosap at protein more
than at mRNA level in eHNPCs strongly suggested that this phenom-
enon was due to post-translational events such as the inhibition of
Prosap maturation and secretion.
The intracellular proteolytic conversion of Prosap to mature Saps
has been well characterized in human ﬁbroblasts [38]. Prosap is
synthesized as a ~55-kDa protein, post-translationally modiﬁed to a
65-kDa glycosylated form and further glycosylated in the Golgi com-
partment to a 70-kDa product. The 65 kDa form is sorted to the
lysosomes where it is almost completely converted into four small
glycoproteins, Sap A, B, C, and D, while the 70-kDa form is exported as
such into the external medium. In eHNPCs the intracellular Prosap is
hardly converted into mature Saps, strongly suggesting an impaired
transport from the Golgi to the late endosomes/lysosomes where Saps
are usually produced [14,38,44]. Most of the lysosomal proteins are
targeted to the lysosomes via mannose-6-phosphate (M6P) receptors,
after acquiring M6P residues while traversing the cis-compartment of
the Golgi apparatus [45]. However, recent studies have indicated that
Prosap and other lysosomal proteins such as the GM2 activator and
acid sphingomyelinase poorly interact with the M6Preceptors, but
rather utilize alternativemechanisms and alternative receptors such as
sortilin, for lysosomal sorting [15,46]. Sortilin, also called neurotensin
receptor 3, is a member of a family of Vps10p-domain receptors,
expressed in a variety of tissues, notably brain, spinal cord and muscle
[47]. The sortilin role as a mediator of lysosomal trafﬁcking of Prosap
was conﬁrmed by the ﬁnding that sortilin inhibition or structural
modiﬁcations prevents the transport of Prosap from the trans Golgi to
the lysosomes [15]. By Western blot analysis we have found that the
sortilin protein was present in eHNPCs homogenate (data not shown).
This observation suggests that the altered Prosap transport in eHNPCs
is not due to the lack of sortilin expression.
In several cell types a speciﬁc relationship between the glycosyla-
tion state of Prosap and its intra or extracellular destination has been
observed. In fact, the secreted form usually contains complex carbo-
hydrate chains, being endo H-resistant, while the intracellular Prosap
form, assigned to be converted into Saps in late endosomes/lysosomes,
contains only high mannose sugars, being endo H-sensitive [14,38].
Conversely, the present ﬁndings indicate that in eHNPCs intracellular
Prosap contains both highmannose and complex type oligosaccharide
chains, suggesting that Prosap, after reaching the cis region of the Golgiapparatus, where it is glycosylated with high mannose type chains,
proceeds towards the trans cisternae acquiring also complex sugar
chains. The difference in the N-linked oligosaccharides indicates a
different transport through the Golgi compartments of intracellular
Prosap contained in eHNPCs or in other cell types such as human
ﬁbroblasts.
The present study shows that in eHNPC also the sorting of proCath
D, a protein that has been proposed to travel together with Prosap
[32], is altered. It is known that the intracellular conversion of the
inactive precursor proCath D (52 kDa) into a single-chain intermediate
form (48–45 kDa) take place in a late-Golgi compartment, while the
successive limited proteolysis of the intermediate form to give rise to
mature two-chain Cath D (30 kDa) occurs in mature, dense lysosomes
[48]. In eHNPCs proCath D was mainly processed to the intermediate
rather than to themature form, suggesting that the transport of Cath D
to the lysosomes was inhibited likewise that of Prosap. In some cell
lines such as HepG2 or breast and ovarian cancer cells the formation of
a complex between Prosap and proCath D in their way from the Golgi
to the lysosomes has been shown [49,50]. It has been proposed that
the formation of this complexmight play a role in the intracellular and
extracellular trafﬁcking of the two precursors [32]. The shared block of
the sorting/processing machinery of Prosap and proCath D in eHNPCs
indicates that their complex (if it is formed at all) cannot reach its ﬁnal
destination/s, namely the lysosomes and/or the medium outside the
cells.
The incapacity of Prosap to reach lysosomes in eHNPCs was
conﬁrmed by confocal microscopy, which revealed that Prosap was
rather located on and near the cell surface in the undifferentiated cells.
Interestingly, the occurrence of Prosap as a surface membrane
component has been previously observed in mouse neuroblastoma
cells [51]. It was concluded that Prosap can follow three different
pathways; one to the lysosomes as precursor of mature saposins,
another one to the extracellular space as a secreted form, and a third
one as a membrane component of neuronal plasma membranes.
While neuronal cells have been reported to have all three Prosap pools
[51], eHNPCs appear to have only the pool located near the cell
surface.
The sorting/processing block of Prosap and proCath D appears to
be overcome during the course of differentiation of eHNPCs into a
mixed population of astrocytes and neurons. The analysis of the
protein expression proﬁles revealed that the lysosomal conversion of
Prosap to Saps and of proCath D to mature Cath D only occurred when
the cells were differentiated. The confocal microscopy conﬁrmed the
lysosomal localization of the mature forms of Sap C and Cath D in the
differentiated cells. Concomitantly, a parallel increase of the Prosap
and proCath D secretion was observed, consistent with the existence
of a common, cell differentiation-regulated, sorting mechanism.
The expression of Prosap–Saps and ProCath–Cath D in undiffer-
entiated eHNPCs most likely has a physiological signiﬁcance. The
complex mechanisms controlling the survival, proliferation and
regenerative capacity of neural stem cells are still poorly understood.
eHNPCs have been shown to be completely resistant to apoptosis
induced by death receptor ligands such as TNF-α [35]. In this context it
is interesting to note that Prosap treatment is able to protect neuronal
and non neuronal (U937) cells from TNF-α-induced cell death [52]. It
is thus reasonable to hypothesize that the accumulated intracellular
Prosap might constitute an additional protective factor involved in the
antiapoptotic machinery of eHNPCs.
On the other hand, also the extremely low level of mature Cath D
protein assessed in eHNPCs might protect these cells from apoptosis.
Several reports have demonstrated that Cath D is a central mediator of
the apoptotic response and participates in apoptosis execution. A role
of Cath D in cell death pathways is well documented, with evidence
that Cath D is a mediator of caspase activation [53,54]. Antisense-
mediated inhibition of Cath D expression and activity inhibits apo-
ptosis caused by interferon-gamma, Fas/APO-1 and TNF-α [33].
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apoptopic events [54]. In eHNPCs the low expression and activity of
mature Cath D might contribute to the resistance of these cells to
apoptotic stimuli. It must be noted that the low Cath D activity here
measured at pH 4.5 in the cell homogenate might be even an
overestimation of the actual activity expressed ‘in vivo’, since the
predominant intermediate form of Cath D present in eHNPCs is
presumably localized in less acidic organelles than mature lysosomes,
where the low pH can fully promote the potential protease activity.
The Prosap gene has a 9 bp exon (exon 8) that can be alternatively
spliced generating threemRNAs, having a stretchof 9 or6 or 0 additional
bases within the Sap B coding region [42]. The expression of mRNA
containingexon8 is tissue speciﬁc, its level beinghigh in brain, heart and
skeletalmuscle [22,42]. Although it remainsunclearwhich is the speciﬁc
function of the different mRNA forms, past data have shown that the
splicingof ProsapmRNA is crucially regulatedduring nerve regenerative
processes and that the percentage of Prosap mRNA without exon 8
dramatically increases in rat brain in response to brain injury, the change
being mostly restricted in the lesion area [22]. A similar increase of this
Prosap mRNA form has been observed following differentiation of
eHNPCs (see Fig. 8) into a mixed neural population in which astrocytes
predominate. The analogous alternative Prosap mRNA splicing after
brain injury and after eHNPCs differentiation strongly suggests that
differentiation of endogenous neural stem/progenitor cells might
contribute to the elevation of the Prosap mRNA form without exon 8
occurring in the brain lesion area. This hypothesis is supported by recent
ﬁnding showing that neural precursors signiﬁcantly proliferate in
response to traumatic brain injury and most of the proliferating cells
differentiate into activated astrocytes [55].
In conclusion, the present results have shown for the ﬁrst time that
in eHNPCs the maturation and secretion of Prosap and proCath D are
blocked and that these biological processes only occur after cell
differentiation. Although our ﬁndings relate to studies in cultured
cells, most likely they reﬂect the ‘in vivo’ situation. Recently, protein
proﬁles have been carried out on several stem cell populations [56,57],
most of the studies being concentrated on the relative abundance of
proteins. However, another important aspect of proteomic analyses is
the study of post-translational modiﬁcations, which can affect the
activity and function of proteins. This is particular true for those
proteins whose ﬁnal destination are lysosomes, where the low pH
promotes the last steps of their maturation and regulates their activity
and function [36]. Prosap–Saps and proCath–Cath D have been shown
to have several potential functions that are modulated not only by
their level but also by their degree of maturation, by the pH of the
environment and by their localization inside or outside the cells. Our
results on the distinct behaviour of these twomultifunctional proteins
in eHNPCs and in their differentiated progeny provide new basis for a
more detailed understanding of neural stem cell biology.
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